CD94 deficiency or blockade unleashes the anti-tumor immunity in mice and humanized murine models

NKG2 family members have emerged as promising targets in tumor immunotherapy. CD94 can dimerize with both inhibitory and activating NKG2 proteins, while the overall effect and value of targeting CD94 on anti-tumor immunity are unclear. We used single cell RNA-seq reveal a remodeled tumor microenvironment in CD94-KO mice, with a reduction in immunosuppressive cells and an increase in anti-tumor immune cells. Overall design: CD45+ tumor-infiltrating lymphocytes were sorted from subcutaneous tumor tissues of WT and CD94-KO mice and analyzed using scRNA-seq (per scRNA-seq data derived from 5 tumor-bearing mice).